569660-97-5

Basic information

• Product Name: (R)-tert-butyl 3-bromopyrrolidine-1-carboxylate
• Synonyms: (R)-tert-butyl 3-bromopyrrolidine-1-carboxylate;(3R)-3-Bromo-1-pyrrolidinecarboxylic acid tert-butyl ester
• CAS NO: 569660-97-5
• Molecular Formula: C9H16BrNO2
• Molecular Weight: 250
• Mol File: 569660-97-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 278℃
• Flash Point: 122℃
• Appearance: /
• Density: 1.379
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: -3.30±0.40(Predicted)
• CAS DataBase Reference: (R)-tert-butyl 3-bromopyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-tert-butyl 3-bromopyrrolidine-1-carboxylate(569660-97-5)
• EPA Substance Registry System: (R)-tert-butyl 3-bromopyrrolidine-1-carboxylate(569660-97-5)

Safety Data

• HazardClass: 9
• Hazardous Substances Data: 569660-97-5(Hazardous Substances Data)

Usage

Uses

It is used as a pharmaceutical intermediate.

InChI:InChI=1S/C9H16BrNO2/c1-9(2,3)13-8(12)11-5-4-7(10)6-11/h7H,4-6H2,1-3H3/t7-/m1/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 103057-44-9 N-(tert-butoxycarbonyl)-3-hydroxypyrrolidine 
• 109431-87-0 (R)-tert-butyl 3-hydroxypyrrolidine-1-carboxylate 

Downstream Products

• 1201657-89-7 tert-butyl 3-(4-bromo-1H-pyrazol-1-yl) pyrrolidine-1-carboxylate 
• 1312712-22-3 C₁₅H₂₈BNO₄ 
• 147410-43-3 tert-butyl 3-phenylpyrrolidine-1-carboxylate 
• 518063-52-0 tert-butyl 3-fluoropyrrolidine-1-carboxylate 
• 1141488-38-1 tert-butyl (3R)-3-[(5-aminopyridin-2-yl)oxy]pyrrolidine-1-carboxylate 
• 1126430-56-5 tert-butyl (3R)-3-[(5-nitropyridin-2-yl)oxy]pyrrolidine-1-carboxylate 
• 1510865-73-2 tert-butyl 3-(4-methoxyphenyl)pyrrolidine-1-carboxylate 

Relevant articles and documents

Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site

Inhibition of the epidermal growth factor receptor represents one of the most promising strategies in the treatment of lung cancer. Acquired resistance compromises the clinical efficacy of EGFR inhibitors during long-term treatment. The recently discovered EGFR-C797S mutation causes resistance against third-generation EGFR inhibitors. Here we present a rational approach based on extending the inhibition profile of a p38 MAP kinase inhibitor toward mutant EGFR inhibition. We used a privileged scaffold with proven cellular potency as well as in vivo efficacy and low toxicity. Guided by molecular modeling, we synthesized and studied the structure-activity relationship of 40 compounds against clinically relevant EGFR mutants. We successfully improved the cellular EGFR inhibition down to the low nanomolar range with covalently binding inhibitors against a gefitinib resistant T790M mutant cell line. We identified additional noncovalent interactions, which allowed us to develop metabolically stable inhibitors with high activities against the osimertinib resistant L858R/T790M/C797S mutant.

BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES

This invention provides compounds of Formula I which are PAFR antagonists: I and the pharmaceutically acceptable salts thereof. The compounds are useful for treating PAF-mediated disorders, and can be used in methods for treating atherosclerosis and preve

SMALL MOLECULE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES (PRMTS)

The present invention relates to compounds that are useful as inhibitors of protein arginine methyltransferase that have a formula selected from Formula (I), Formula (II) and Formula (III), as well as racemic mixtures, diastereomers, enantiomers and tautomers thereof and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof as defined herein. Said compound are useful as inhibitors of PRMTs and/or CARM-I. The invention further relates to compositions comprising such compounds and methods for their use.